A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of SGN-LIV1A in Patients With LIV-1-Positive Metastatic Breast Cancer
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2017
At a glance
- Drugs SGN LIV1A (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors Seattle Genetics
- 26 Jul 2017 Planned End Date changed from 1 May 2018 to 1 Dec 2019.
- 26 Jul 2017 Planned primary completion date changed from 1 Feb 2018 to 1 Dec 2018.
- 09 Feb 2017 According to a Seattle Genetics media release, enrollment is ongoing for an expansion cohort and to evaluate SGN-LIV1A in combination with trastuzumab (Herceptin).
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History